Integra Lifesciences Holdings Corp (IART) — SEC Filings
Integra Lifesciences Holdings Corp (IART) — 29 SEC filings. Latest: 8-K (May 5, 2026). Includes 8 8-K, 8 SC 13G/A, 6 10-Q.
View Integra Lifesciences Holdings Corp on SEC EDGAR
Overview
Integra Lifesciences Holdings Corp (IART) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Integra LifeSciences Holdings Corp. announced on December 11, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and the election of new directors, alongside updates to executive compensation arrangements.
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 24 neutral. The dominant filing sentiment for Integra Lifesciences Holdings Corp is neutral.
Filing Type Overview
Integra Lifesciences Holdings Corp (IART) has filed 8 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 2 SC 13G, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of IART's 23 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.20B |
| Net Income | $ -514.77M |
| EPS | $ -6.72 |
| Debt-to-Equity | N/A |
| Cash Position | $232.19M |
| Operating Margin | -43.0% |
| Total Assets | $3.65B |
| Total Debt | $1.75B |
Key Executives
- DeWitte
- Arduini
- Michael McBreen
Industry Context
Integra LifeSciences operates in the highly competitive medical technology sector, focusing on surgical instruments, neurosurgery, and regenerative technologies. The industry is characterized by rapid innovation, stringent regulatory oversight (FDA, etc.), and consolidation. Companies like IART face pressure to demonstrate clinical efficacy and cost-effectiveness to gain market share against larger, well-established players and smaller, specialized firms.
Top Tags
amendment (6) · institutional-ownership (6) · healthcare (4) · 10-Q (4) · medical-devices (4) · Medical Devices (3) · acquisition (3) · financials (3) · passive-investing (3) · management-change (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $514.77M | For the nine months ended September 30, 2025, a significant increase from $26.38M in 2024. |
| Goodwill Impairment Charge | $511.37M | Primary driver of the net loss for the nine months ended September 30, 2025. |
| Total Revenue, Net | $1.20B | For the nine months ended September 30, 2025, up from $1.17B in 2024. |
| Long-term Borrowings (Senior Credit Facility) | $1.71B | As of September 30, 2025, a substantial increase from $1.09B at December 31, 2024. |
| Convertible Securities | $573.17M | Reduced from $573.17M at December 31, 2024, to zero at September 30, 2025, indicating repayment. |
| Employee Termination Costs (Payments) | $8.13M | Incurred for restructuring activities during the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $232.19M | As of September 30, 2025, a decrease from $246.38M at December 31, 2024. |
| Total Revenue, Net (Q3) | $402.06M | For the three months ended September 30, 2025, up from $380.83M in 2024. |
| Net Income (Prior Year) | $22.4M | for the three months ended June 30, 2024, highlighting the swing to loss |
| Acquisition Value | $1.0B | Total consideration for Integra LifeSciences |
| Expected Closing | Q3 2025 | Anticipated timeframe for the transaction to be finalized |
| Fiscal Year | 2024 | Reporting period for the 10-K filing. |
| Fiscal Year End | 1231 | Indicates the end date of the reporting fiscal year. |
| Filing Date | 20250225 | Date the 10-K was officially filed with the SEC. |
| SEC File Number | 000-26224 | Unique identifier for the company's SEC filings. |
Forward-Looking Statements
- {"claim":"Other institutional investors may increase their positions in Integra LifeSciences, following Capital Research Global Investors' lead.","entity":"Integra LifeSciences Holdings Corp.","targetDate":"Within 6 months","confidence":"medium"}
- {"claim":"Other institutional investors may review their positions in Integra LifeSciences following Wellington's reduced stake.","entity":"Integra LifeSciences Holdings Corp","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Integra Lifesciences Holdings Corp (IART)?
Integra Lifesciences Holdings Corp has 29 recent SEC filings from Jan 2024 to May 2026, including 8 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IART filings?
Across 29 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 24 neutral. The dominant sentiment is neutral.
Where can I find Integra Lifesciences Holdings Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Integra Lifesciences Holdings Corp (IART) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Integra Lifesciences Holdings Corp?
Key financial highlights from Integra Lifesciences Holdings Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IART?
The investment thesis for IART includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Integra Lifesciences Holdings Corp?
Key executives identified across Integra Lifesciences Holdings Corp's filings include DeWitte, Arduini, Michael McBreen.
What are the main risk factors for Integra Lifesciences Holdings Corp stock?
Of IART's 23 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Integra Lifesciences Holdings Corp?
Recent forward-looking statements from Integra Lifesciences Holdings Corp include guidance on {"claim":"Other institutional investors may increase their positions in Integra LifeSciences, following Capital Research and 1 other predictions.